Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Debt / NOTE 2.250% 4/0
-
Number of holders
-
38
-
Total principal
-
555M
-
Principal change
-
-10.1M
-
Total reported value, excl. options
-
$647M
-
Value change
-
-$19.8B
-
Number of buys
-
19
-
Number of sells
-
-16
-
Price
-
$1.15
Significant Holders of ASCENDIS PHARMA A/S - NOTE 2.250% 4/0 as of Q1 2024
37 filings reported holding 04351PAD3 - ASCENDIS PHARMA A/S - NOTE 2.250% 4/0 as of Q1 2024.
ASCENDIS PHARMA A/S - NOTE 2.250% 4/0 has 38 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $555M of principal
.
Largest 10 bondholders include WOLVERINE ASSET MANAGEMENT LLC ($140M of principal), Linden Advisors LP ($124M of principal), FRANKLIN RESOURCES INC ($46.5M of principal), READYSTATE ASSET MANAGEMENT LP ($42M of principal), AVIVA PLC ($26.2M of principal), CITADEL ADVISORS LLC ($25.8M of principal), Point72 Asset Management, L.P. ($16M of principal), Davidson Kempner Capital Management LP ($15M of principal), ZAZOVE ASSOCIATES LLC ($13.1M of principal), and STATE STREET CORP ($12.4M of principal).
This table shows the top 38 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.